# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 14, 2020 (May 13,2020)

## ICU MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-34634	33-0022692					
(State or other jurisdiction	(2	(IRS Employer					
of incorporation)	(Commission File Number)	Identification No.)					
951 Calle Amaneo	cer , San Clemente , Cali	ifornia 92673					
(Address	s of principal executive offices)	(Zip Code)					
(949) 366-2183 Registrant's telephone number, including area code							
	N/A						
(Former name or former address, if changed since last report)							
Check the appropriate box below if the Form registrant under any of the following provisio							
$\square$ Written communications pursuant to Rul	le 425 under the Securities Act (	(17 CFR 230.425)					
☐ Soliciting material pursuant to Rule 14a-	-						
☐ Pre-commencement communications pur	• •						
☐ Pre-commencement communications pur	rsuant to Rule 13e-4(c) under th	ne Exchange Act (17 CFR 240.13e-4(c))					
Securities registered pursuant to Section 12(b) of the Act:							
Title of each class	Trading Symbol	Name of each exchange on which registered					
		The Nasdaq Stock Market LLC					
Common stock, par value \$0.10 per share	ICUI	(Global Select Market)					
Indicate by check mark whether the regist the Securities Act of 1933 (§230.405 of the 2 of this chapter).	trant is an emerging growth com his chapter) or Rule 12b-2 of the	npany as defined in as defined in Rule 405 of e Securities Exchange Act of 1934 (§240.12b-					
Emerging growth company $\Box$							
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. $\square$							

#### Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2020 annual meeting of stockholders of ICU Medical, Inc. (the "Company") held on May 13, 2020, the following proposals were voted on by the Company's stockholders, as set forth below:

## Proposal 1. Election of directors.

Name of Nominee	Votes For	Withheld	Broker Non- Votes
Vivek Jain	18,719,564	497,362	908,473
George A. Lopez, M.D.	19,063,231	153,695	908,473
Robert S. Swinney, M.D.	18,786,730	430,196	908,473
David C. Greenberg	18,742,971	473,955	908,473
Elisha W. Finney	18,858,385	358,541	908,473
David F. Hoffmeister	19,088,234	128,692	908,473
Donald M. Abbey	18,922,679	294,247	908,473

The Company's stockholders elected each of the director nominees to serve as a director for a term of one year until the 2021 annual meeting of stockholders and until their respective successors are elected and qualified.

Proposal 2. Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.

_	Votes For	Votes Against	Abstain	Broker Non-Votes
	19,896,837	178,068	50,494	_

The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.

Proposal 3. Approve the advisory vote on the Company's named executive officer compensation.

_	Votes For	Votes Against	Abstain	Broker Non-Votes
	18,915,196	256,144	45,586	908,473

The Company's stockholders approved, on an advisory basis, the Company's named executive officer compensation.

## **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ICU MEDICAL, INC.

Date: May 14, 2020 By: /s/ Brian M. Bonnell

Brian M. Bonnell Chief Financial Officer